Truist downgraded Sabra Health Care (SBRA) to Hold from Buy with a price target of $17, down from $18.Stay Ahead of the Market:Discover ...

Truist analyst Michael Lewis downgraded Sabra Health Care (SBRA) to Hold from Buy with a price target of $17, down from $18. The firm cites ...

Sabra Health Care REIT had a net margin of 14.20% and a return on equity of 3.51%. The firm had revenue of $178.00 million for the quarter, compared to analysts’ expectations of $177.19 million.

Truist has recently reduced Sabra Health Care REIT Inc (SBRA) stock to Hold rating, as announced on January 17, 2025, according to Finviz. Earlier, on January 7, 2025, JMP Securities had raised the ...

Dividend stocks form a key part of any stock strategy, as eit Jefferies lowered the firm’s price target on Sabra Health Care to $20 from $21 and keeps a Buy rating on the shares as part of a ...

Sabra Health Care REIT had a return on equity of 3.51% and a net margin of 14.20%. The company had revenue of $178.00 million for the quarter, compared to the consensus estimate of $177.19 million.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...